Metoclopramide-induced tardive dyskinesia in an infant
β Scribed by Nicte I. Mejia; Joseph Jankovic
- Publisher
- John Wiley and Sons
- Year
- 2004
- Tongue
- English
- Weight
- 63 KB
- Volume
- 20
- Category
- Article
- ISSN
- 0885-3185
No coin nor oath required. For personal study only.
β¦ Synopsis
Abstract
We describe a 1βyearβold girl who developed orofaciolingual stereotypy at age 2 months after a 17βday treatment with metoclopramide for gastroesophageal reflux. The stereotypy, documented by sequential videos, persisted for at least 9 months after the drug was discontinued. This patient represents the first documented case of tardive dyskinesia in an infant. We also review previous reports of tardive dyskinesia in children. Β© 2004 Movement Disorder Society
π SIMILAR VOLUMES
Levetiracetam (LEV), a novel antiepileptic drug, has demonstrated antidyskinetic effect in preclinical animal models of Parkinson's disease (PD) and in one open label study in PD patients with levodopa-induced dyskinesia. The acute antidyskinetic effects of LEV in patients with tardive dyskinesia we
We examined whether an oral challenge dose of the amino acid phenylalanine (a dopamine precursor) exacerbates the abnormal movements of tardive dyskinesia (TD). We also examined age, gender, treatment duration, and baseline movement severity in relation to phenylalanine-induced changes in movements.
## Abstract It is common for patients with idiopathic Parkinson's disease to develop levodopaβinduced dyskinesia. This report provides what we believe is the first videotape presentation of levodopaβinduced dyskinesia in a patient with progressive supranuclear palsy. To our knowledge, there is only